Show simple item record

dc.contributor.authorGirón Ortega, José Antonio
dc.contributor.authorMárquez Coello, María de las Mercedes 
dc.contributor.authorGutiérrez Saborido, Daniel
dc.contributor.authorArizcorreta Yarza, Ana 
dc.contributor.authorCuesta Sancho, Sara
dc.contributor.authorGirón González, José Antonio 
dc.contributor.otherBiomedicina, Biotecnología y Salud Públicaes_ES
dc.contributor.otherMedicinaes_ES
dc.date.accessioned2024-11-21T10:34:11Z
dc.date.available2024-11-21T10:34:11Z
dc.date.issued2021
dc.identifier.issn1435-4373
dc.identifier.issn0934-9723
dc.identifier.urihttp://hdl.handle.net/10498/33879
dc.description.abstractTo analyze the modifications of CD4 T cell, CD4/CD8 ratio, and serum levels of soluble CD14 (sCD14) in HIV/HCV-coinfected patients after treatment with direct anti-HCV antiviral agents. Consecutive cases of HIV/HCV-coinfected patients, attended at the University Hospital, who achieved sustained virological responses with interferon-free hepatitis C antiviral drugs, were analyzed. Thirty-five percent of patients (n = 39) had been diagnosed with liver cirrhosis. The evaluation criteria were changes in CD4 T-cell counts and percentages and inflammation (measured by serum sCD14 levels) or immune activation indexes (determined by CD4/CD8 ratio) from beginning anti-HCV therapy to 12 months later. One hundred twelve patients were included (87% male; median age, 54 years; median time from the infection diagnosis, 22 years; previous drug users, 87%). Significant increases in CD4 T cell count and percentage were detected only in individuals without liver cirrhosis. No significant differences in CD4/CD8 ratios or sCD14 levels were observed in patients with or without cirrhosis. The proportion of patients with less than 500 CD4 T cell/mm3 before therapy who achieved more than 500 CD4 T cell/mm3 after it increased only in the group without liver cirrhosis. The finding that CD4 T cell count and percentage were improved only in patients without liver cirrhosis supports the idea that treatment against HCV in HIV/HCV-coinfected patients is needed in the early phases of liver disease.es_ES
dc.description.sponsorshipSecretaría General de Investigación, Desarrollo e Innovación en Salud, Junta de Andalucía, Iniciativa Territorial Integrada 2014-2020 para la provincia de Cádiz (No PI-0076-2017), Spain. Co-financed by FEDER (Fondo Europeo de Desarrollo Regional).es_ES
dc.formatapplication/pdfes_ES
dc.language.isoenges_ES
dc.publisherSPRINGERes_ES
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.sourceEur J Clin Microbiol Infect Dis. 2021 Sep;40(9):1863-1871.es_ES
dc.subjectHIV infectiones_ES
dc.subjectHepatitis C viruses_ES
dc.subjectCD4 T cellses_ES
dc.subjectCD8 T cellses_ES
dc.subjectCD4/CD8 ratioes_ES
dc.subjectSoluble CD14es_ES
dc.subjectDirect-acting antiviral agentses_ES
dc.subjectSustained viral responsees_ES
dc.titleModifications of CD4 T cells, CD4/CD8 ratio and serum levels of soluble CD14 in HIV-HCV-coinfected patients after sustained HCV response induced by direct-acting antiviral agents: influence of liver cirrhosises_ES
dc.typejournal articlees_ES
dc.rights.accessRightsclosed accesses_ES
dc.identifier.doi10.1007/s10096-021-04237-y.
dc.relation.projectIDinfo:eu-repo/grantAgreement/ISCIII/Plan Estatal de Investigación Científica y Técnica y de Innovación 2017-2020 (ISCIII)/PI19%2F01361/ES/INFECCION POR VIH, FORMACION DE NETS Y ATEROSCLEROSIS/es_ES
dc.type.hasVersionVoRes_ES


Files in this item

This item appears in the following Collection(s)

Show simple item record

Attribution-NonCommercial-NoDerivatives 4.0 Internacional
This work is under a Creative Commons License Attribution-NonCommercial-NoDerivatives 4.0 Internacional